论文部分内容阅读
吉非替尼(易瑞沙,Iressa)是一种选择性表皮生长因子受体(EGFR)酪氨酸激酶抑制剂,该酶通常表达于上皮来源的实体瘤。对于EGFR酪氨酸激酶活性的抑制可妨碍肿瘤的生长、转移和血管生成,并增加肿瘤细胞的凋亡。我科自2005年2月至12月用易瑞沙治疗晚期非小细胞肺癌5例,现报告如下。
Gefitinib (Iressa) is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is normally expressed in epithelial-derived solid tumors. Inhibition of EGFR tyrosine kinase activity can hinder tumor growth, metastasis and angiogenesis and increase tumor cell apoptosis. Our department from February 2005 to December with Iressa treatment of advanced non-small cell lung cancer in 5 cases, are as follows.